



UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE
United States Patent and Trademark Office
Address: COMMISSIONER FOR PATENTS
P.O. Box 1450
Alexandria, Virginia 22313-1450
www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
09/391,762	09/08/1999	KEVIN WEADOCK	498-36-RES	9047
23869	7590	11/30/2005		
HOFFMANN & BARON, LLP 6900 JERICHO TURNPIKE SYOSSET, NY 11791			EXAMINER PREBILIC, PAUL B	
			ART UNIT	PAPER NUMBER

3738

DATE MAILED: 11/30/2005

Please find below and/or attached an Office communication concerning this application or proceeding.

Office Action Summary

Application No.

09/391,762

Applicant(s)

WEADOCK ET AL.

Examiner

Paul B. Prebilic

Art Unit

3738

-- The MAILING DATE of this communication appears on the cover sheet with the correspondence address --

Period for Reply

A SHORTENED STATUTORY PERIOD FOR REPLY IS SET TO EXPIRE 3 MONTH(S) OR THIRTY (30) DAYS, WHICHEVER IS LONGER, FROM THE MAILING DATE OF THIS COMMUNICATION.

- Extensions of time may be available under the provisions of 37 CFR 1.136(a). In no event, however, may a reply be timely filed after SIX (6) MONTHS from the mailing date of this communication.
- If NO period for reply is specified above, the maximum statutory period will apply and will expire SIX (6) MONTHS from the mailing date of this communication.
- Failure to reply within the set or extended period for reply will, by statute, cause the application to become ABANDONED (35 U.S.C. § 133). Any reply received by the Office later than three months after the mailing date of this communication, even if timely filed, may reduce any earned patent term adjustment. See 37 CFR 1.704(b).

Status

- 1) ☒ Responsive to communication(s) filed on 07 November 2005.
- 2a) ☒ This action is **FINAL**. 2b) ☐ This action is non-final.
- 3) ☐ Since this application is in condition for allowance except for formal matters, prosecution as to the merits is closed in accordance with the practice under *Ex parte Quayle*, 1935 C.D. 11, 453 O.G. 213.

Disposition of Claims

- 4) ☒ Claim(s) 1-4,7 and 9-31 is/are pending in the application.
- 4a) Of the above claim(s) _____ is/are withdrawn from consideration.
- 5) ☐ Claim(s) _____ is/are allowed.
- 6) ☒ Claim(s) 1-4,7 and 9-31 is/are rejected.
- 7) ☐ Claim(s) _____ is/are objected to.
- 8) ☐ Claim(s) _____ are subject to restriction and/or election requirement.

Application Papers

- 9) ☐ The specification is objected to by the Examiner.
- 10) ☐ The drawing(s) filed on _____ is/are: a) ☐ accepted or b) ☐ objected to by the Examiner.
Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a).
Replacement drawing sheet(s) including the correction is required if the drawing(s) is objected to. See 37 CFR 1.121(d).
- 11) ☐ The oath or declaration is objected to by the Examiner. Note the attached Office Action or form PTO-152.

Priority under 35 U.S.C. § 119

- 12) ☐ Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).
- a) ☐ All b) ☐ Some * c) ☐ None of:
- ☐ Certified copies of the priority documents have been received.
 - ☐ Certified copies of the priority documents have been received in Application No. _____.
 - ☐ Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)).

* See the attached detailed Office action for a list of the certified copies not received.

Attachment(s)

- ☐ Notice of References Cited (PTO-892)
- ☐ Notice of Draftsperson's Patent Drawing Review (PTO-948)
- ☒ Information Disclosure Statement(s) (PTO-1449 or PTO/SB/08)
Paper No(s)/Mail Date 6/6/05.
- ☐ Interview Summary (PTO-413)
Paper No(s)/Mail Date. _____.
- ☐ Notice of Informal Patent Application (PTO-152)
- ☐ Other: _____.

Claim Rejections - 35 USC § 112

The following is a quotation of the second paragraph of 35 U.S.C. 112:

The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the applicant regards as his invention.

Claims 17, 18, and 28 are rejected under 35 U.S.C. 112, second paragraph, as being indefinite for failing to particularly point out and distinctly claim the subject matter which applicant regards as the invention.

Claims 17 and 18 are indefinite because they now contradict claim 13 that requires "a biodegradable composition having an acidic pH" contained in the pores. For this reason, it appears that Applicants are claiming two states of the invention at the same time. The amendment of November 3, 2005 did not make the claim language any more definite and it appears that the new claim language lacks clear original support. This is due to the fact that the solution (i.e. water of the solution) would dissolve the buffered phosphate and the pH would no longer be acidic. Furthermore, the pH is a measure of a solution characteristic and not a composition characteristic. Furthermore, it is unclear how "said buffered phosphate is maintained at a pH of about 7.4" (see claim 18) since pH is a measure of a solution concentration of hydrogen atoms.

Claim 28 contradicts base claim 13 that requires an acidic solution, yet the present claims attempts to claim a pH-adjusted solution. For this reason, it is unclear which of these two products are being set forth such that claim scope is considered indefinite.

Claims 1-4, 7, and 9-31 are rejected under 35 U.S.C. 251 as being an improper recapture of broadened claimed subject matter surrendered in the application for the

Art Unit: 3738

patent upon which the present reissue is based. See *Hester Industries, Inc. v. Stein, Inc.*, 142 F.3d 1472, 46 USPQ2d 1641 (Fed. Cir. 1998); *In re Clement*, 131 F.3d 1464, 45 USPQ2d 1161 (Fed. Cir. 1997); *Ball Corp. v. United States*, 729 F.2d 1429, 1436, 221 USPQ 289, 295 (Fed. Cir. 1984). A broadening aspect is present in the reissue, which was not present in the application for patent. The record of the application for the patent shows that the broadening aspect (in the reissue) relates to subject matter that Applicants previously surrendered during the prosecution of the application.

Accordingly, the narrow scope of the claims in the patent was not an error within the scope of 35 U.S.C. 251, and the broader scope surrendered in the application for the patent cannot be recaptured by the filing of a reissue application.

Present claims 1-4, 7, and 9-31 are improper for a reissue application because they attempt to recapture subject matter surrendered in order to overcome a prior art rejection. Specifically, during the pendency of the patented file 08/289,790, the language "filled with fluid which solidifies and is crosslinked to form" and "said material being insoluble at a pH of about 7.4" was added in order to overcome a prior art rejection; see the Examiner's Answer dated March 12, 2002 under the heading "Issue 1" on pages 8 to 11, which is incorporated herein by reference. Therefore, it is improper to attempt to recapture this subject matter via claims 1-4, 7, and 9-31 in the present reissue application.

Claim Rejections Based Upon Prior Art

The following is a quotation of the appropriate paragraphs of 35 U.S.C. 102 that form the basis for the rejections under this section made in this Office action:

Art Unit: 3738

A person shall be entitled to a patent unless –

(b) the invention was patented or described in a printed publication in this or a foreign country or in public use or on sale in this country, more than one year prior to the date of application for patent in the United States.

The following is a quotation of 35 U.S.C. 103(a) which forms the basis for all obviousness rejections set forth in this Office action:

(a) A patent may not be obtained though the invention is not identically disclosed or described as set forth in section 102 of this title, if the differences between the subject matter sought to be patented and the prior art are such that the subject matter as a whole would have been obvious at the time the invention was made to a person having ordinary skill in the art to which said subject matter pertains. Patentability shall not be negated by the manner in which the invention was made.

Claims 1-4, 7, and 21-25 are rejected under 35 U.S.C. 102(b) as anticipated by Kaehler et al (journal article entitled "Precoating Substrate and Surface Configuration . . .") or, in the alternative, under 35 U.S.C. 103(a) as obvious over Kaehler et al (journal article entitled "Precoating Substrate and Surface Configuration . . .") alone. The following is paraphrased from the Board of Appeals decision rendered July 21, 2003, the rejection of claim 13 on page 8 of the decision. Kaehler describes a vascular graft which comprises a body of PTFE having a structure of spaced-apart nodes interconnected by fibrils having pores present between the fibrils and nodes. The vascular grafts used in Kaehler are reinforced (see Kaehler, page 536, left hand column, "Graft material") which are also described in the '114 patent as being e-PTFE on column 1, lines 56-63. The vascular grafts of Kaehler contain the nodes and fibril structure claimed as seen from a complete reading of Kaehler; see, for example, the paragraph bridging the two columns on page 537. The claims require that the implantable member of e-PTFE contains a biodegradable composition of natural origin in its pores. On page 536, Kaehler teaches forcing type I and III collagen through the

Art Unit: 3738

graft repeatedly until it was almost impossible to force any more through; see page 536, first full paragraph. This collagen is the same as the "solid precipitate of a material of natural origin formed *in situ* from a solution that is pH-adjusted within the pores" because it is collagen that is pH adjusted outside the pores (see *supra*) and then forced through the pores. Even though a different method is used, the same product results because pH adjusted collagen ends up in the pores of the same substrate as claimed; see MPEP 2113, which is incorporated herein by reference.

Alternatively, since a different method is used to make the product, one may reason that a different product results. However, the Examiner asserts that any difference is only slight such that the claimed invention is at least obvious in view of Kaehler alone. For this reason, the Examiner the claimed product would have been considered at least obvious to an ordinary artisan in the art.

Claims 9 and 10 are rejected under 35 U.S.C. 103(a) as being unpatentable over Kaehler (journal article entitled "Precoating Substrate . . . ") in view of Hoffman, Jr. et al (US 5,197,977). Kaehler meets or renders obvious the claim language as explained *supra* but fails to disclose the use of a pharmacological agent as claimed. However, Hoffman teaches that it was known to use pharmacological agents in similar grafts within the art; see the paragraph bridging columns 5 and 6. Therefore, it would have been considered *prima facie* obvious to an ordinary artisan to include a pharmacological agent in the Kaehler implant for the same reasons that Hoffman teaches doing the same.

Claims 11 and 12 are rejected under 35 U.S.C. 103(a) as being unpatentable over Kaehler (journal article entitled "Precoating Substrate . . . ") in view of Tran et al (article entitled "Plasma Modification. . ."). Kaehler meets or renders obvious the claim invention as explained *supra*, but fails to teach modifying the substrate to enhance its hydrophilic character (claim 11) by subjecting the polytetrafluoroethylene to plasma deposition (claim 12). However, Tran also describes polytetrafluoroethylene grafts, which are coated with collagen, and which have been pretreated to make them more hydrophilic by plasma deposition; see page 374 and page 379 including Table III. Therefore, it would have been considered *prima facie* obvious to an ordinary artisan to pretreat the graft of Kaehler to make it hydrophilic via plasma deposition in order to render the graft more receptive to collagen impregnation as taught by Tran.

Claims 26 and 27 are rejected under 35 U.S.C. 103(a) as being unpatentable over Kaehler et al (journal article entitled "Precoating Substrate . . . ") in view of Alonso (US 5,037,377). Kaehler meets or renders obvious the claim language as explained *supra*, but fails to disclose the pH of the phosphate buffer as claimed. However, Alonso teaches the phosphate buffers having pH's of 7.4 were known to the same art; see column 3, lines 31-41. Therefore, it is the Examiner's position that it would have been considered *prima facie* obvious to an ordinary artisan to use a 7.4 pH phosphate buffer for the same reasons that Alonso uses the same.

Claims 13-18 and 29-31 are rejected under 35 U.S.C. 102(b) as anticipated by Kodama et al (US 5,028,597) [~~Kaehler (journal article entitled "Precoating Substrate . . . ")~~] or, in the alternative, under 35 U.S.C. 103(a) as obvious over Kodama et al (US

Art Unit: 3738

5,028,597) in view of Kaehler (journal article entitled "Precoating Substrate . . . ") or Hoffman, Jr. et al (US 5,197,977). Kodama discloses impregnating or coating an expanded PTFE graft with collagen to render it antithrombogenic and biocompatible; see the abstract, column 2, lines 65-68, column 4, lines 28-38, and Examples 2 and 5. Since the pores of the PTFE substrate are open on the surface of the graft, the Examiner reasons that the pores would inherently be at least partially filled with "a biodegradable composition having an acidic pH" in the form of collagen; see particularly column 4, lines 21-28 and lines 50-60. The Examiner reasons that collagen is "capable of forming a precipitate that substantially fills said pores at selected conditions of temperature and pH to form an insoluble substrate site for cellular attachment" because the it is the same material as that disclosed and claimed by the Applicants.

Alternatively, it is not clear that impregnation of collagen is within the pores as claimed because it is not explicitly disclosed as such. However, both Kaehler and Hoffman teach that is was known to impregnate collagen throughout the pores of the same or similar type substrate by forcing or massaging a solution thereof therethrough. For this reason, the Examiner asserts that it would have been at least obvious to impregnate the collagen of Kodama so that it is within the pores to a greater extent so as to make the graft thereof blood tight and for the same reasons that Kaehler or Hoffman do the same.

Regarding claims 17 and 18, since the limitations of these claims apparently contradict base claim 13, the Examiner asserts that claim 13 controls and that the claim language is fully met when given the claim 13 interpretation.

Claims 19 and 20 are rejected under 35 U.S.C. 103(a) as being unpatentable over Kodama, Hoffman, and Kaehler as applied to claims 13-18 and 29-31 above, and further in view of Hoffman, Jr. et al (US 5,197,977). Kodama meets or renders obvious the claim language as explained *supra* but fails to disclose the use of a pharmacological agent as claimed. However, Hoffman teaches that it was known to use pharmacological agents in similar grafts within the art; see the paragraph bridging columns 5 and 6. Therefore, it would have been considered *prima facie* obvious to an ordinary artisan to include a pharmacological agent in the Kodama implant for the same reasons that Hoffman teaches doing the same.

Claim 28 is rejected under 35 U.S.C. 103(a) as being unpatentable over Kodama, Hoffman, and Kaehler as applied to claims 13-18 and 29-31 above, and further in view of Alonso (US 5,037,377). Kodama meets or renders obvious the claim language as explained *supra*, but fails to disclose the pH of the phosphate buffer as claimed. However, Alonso teaches the phosphate buffers having pH's of 7.4 were known to the same art; see column 3, lines 31-41. Therefore, it is the Examiner's position that it would have been considered *prima fascia* obvious to an ordinary artisan to use a 7.4 pH phosphate buffer for the same reasons that Alonso uses the same.

Response to Arguments

Applicant's arguments with respect to the present claims have been considered but are considered unpersuasive.

In response to the claims 17, 18, and 28, Section 112, second paragraph rejection traversal that claim 17 has been amended to overcome the indefiniteness, the

Examiner maintains that the Applicants are still attempting to claim two states of the invention in claim 28, and claims 17 and 18 are still indefinite for the reasons stated in the rejection. Therefore, the claims scopes' are considered indefinite because they are not clear which of the two pH's are being required by the claim.

With regard to the 35 USC 251 rejection traversal that the claims are not recapturing surrendered subject matter because there are narrower than the originally filed claims, the Examiner asserts Applicants' standard for recapture is not proper. Specifically, if Applicants made amendments to overcome prior art rejections, as is the situation here, it is not proper to leave out these limitations in reissue claims; see MPEP 1412.02, which is incorporated herein by reference.

Although Applicants can modify or broaden the limitations relied upon for patentability, they cannot be entirely elimination as Applicants have done. For these reasons, the Examiner asserts that the Applicants are attempting to recapture surrendered subject matter; see MPEP 1412.02 that in incorporated herein by reference.

With regard to the traversals of the prior art rejections, the Applicants argue that the Examiner has not made a Section 103 rejection over Kaehler alone. However, the rejection was clearly made; see pages 4 and 5 of the May 3, 2005 Office action.

Applicants traversal that the claim process limitations of the product claim must be given weight (see page 15 of the November 3, 2005 response), the Examiner asserts that the process limitation have been given patentable weight to the extent that

they should as evidenced by the rejection on pages 4 and 5 of the May 3, 2005 Office action.

Conclusion

THIS ACTION IS MADE FINAL. Applicant is reminded of the extension of time policy as set forth in 37 CFR 1.136(a).

A shortened statutory period for reply to this final action is set to expire THREE MONTHS from the mailing date of this action. In the event a first reply is filed within TWO MONTHS of the mailing date of this final action and the advisory action is not mailed until after the end of the THREE-MONTH shortened statutory period, then the shortened statutory period will expire on the date the advisory action is mailed, and any extension fee pursuant to 37 CFR 1.136(a) will be calculated from the mailing date of the advisory action. In no event, however, will the statutory period for reply expire later than SIX MONTHS from the mailing date of this final action.

Applicant should specifically point out the support for any amendments made to the disclosure, including the claims (MPEP 714.02 and 2163.06). Due to the procedure outlined in MPEP 2163.06 for interpreting claims, it is noted that other art may be applicable under 35 USC 102 or 35 USC 103(a) once the aforementioned issue(s) is/are addressed.

Applicant is respectfully requested to provide a list of all copending applications that set forth similar subject matter to the present claims. A copy of such copending claims is respectfully requested in response to this Office action if the application is not stored in image format (i.e. the IFW system) or published.

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Examiner Paul B. Prebilic whose telephone number is (571) 272-4758. He can normally be reached on 6:30-5:00 M-Th.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, McDermott Corrine can be reached on 571-272-4754. The fax phone

Art Unit: 3738

number for the organization where this application or proceeding is assigned is 571-273-8300.

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see <http://pair-direct.uspto.gov>. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free).

A handwritten signature in black ink, appearing to read "Paul Prebilic", with a stylized flourish extending from the end.

Paul Prebilic
Primary Examiner
Art Unit 3738